Which NVAF patients are candidates for TSOACs?

Slides:



Advertisements
Similar presentations
Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.
Advertisements

The Home INR Study (THINRS): Home INR Monitoring as Effective as Clinic-Based Care AK Jacobson, MD American Heart Association 2008 Scientific Sessions:
Educational Event 23rd & 24th January 2013
Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.
Concomitant Antiplatelet and OAC Tx: Real-World Practice In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic.
Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
CLINICAL CASES.
DR DIPTI CHITNAVIS HAEMATOLOGY CONSULTANT WEST SUFFOLK HOSPITAL JANUARY 2014 Update on the new oral anticoagulants; 12 months on.
Chapter Eight Venous Disease Coalition Safe Use of Oral Anticoagulants VTE Toolkit.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Cross-Canada Collaboration to Promote Evidence-Based Use of Anticoagulants CADTH SYMPOSIUM APRIL 14, 2015.
AF and NOACs An UPDATE JULY 2014
APIXABAN NELLA SPAF 21 maggio 2015 ROMA Dott. Sergio Agosti Cardiologo, Ospedale Novi Ligure (AL)
1 10 points. AF & Warfarin practice Profile 2011.
ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.
LIFE SAVING TECHNOLOGY THAT HAVE ARISEN AS A RESULT OF IMPROVED UNDERSTANDING OF THE CIRCULATORY SYSTEM (ARTIFICIAL HEART VALVES, ECG AND ARTIFICIAL BLOOD)
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
Atrial Fibrillation Now and Then Min-Yen Han,M.D. November 15,2014.
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
Atrial Fibrillation and Anticoagulation
Massachusetts Medical Society, Health Policy/Health Systems 1 Warfarin Survey November 2007.
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
Community Pharmacy Presentation for Hospital Pharmacists July 2015.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Optimising Anticoagulation in the New Oral Anticoagulant Clinic for People with AF Satinder Bhandal Consultant Anticoagulation Pharmacist February 2015.
G UIDELINES FOR THE P ERI -P ROCEDURAL M ANAGEMENT OF A DULTS T AKING T ARGET S PECIFIC A NTICOAGULANTS (TSOAC S ): DABIGATRAN, RIVAROXABAN, APIXABAN,
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Comparison of Patient Satisfaction and Time Spent in Therapeutic Range in Two Different Clinic Models Ashley Pokallus, PharmD PGY1 Pharmacy Resident—Ambulatory.
STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE (STAC) PATIENT SPECIFIC DIRECTION FOR DALTEPARIN (LMWH) FOR PATIENTS WITH VENOUS THROMBO-EMBOLISM (VTE)/MECHANICAL.
Net clinical benefit of OAC
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
PHARMACEUTICAL GUIDELINES: BASIC PRINCIPLES AND STATUTES.
Low Procedural Bleed Risk
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Uttam M Chouhan Pharmacist Glan Clwyd Hospital, BCUHB September 2017
Exploring Factors Associated with Preferential Prescribing of Apixaban Over Warfarin in Patients with Non-Valvular Atrial Fibrillation Scott McColgana,
Paediatric Cardiac Pharmacist Bristol Royal Hospital for Children
An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
Anticoagulation in Atrial Fibrillation
Covering the Bases in Cardioversion
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Randomized Evaluation of Long-term anticoagulant therapY
Click here for title Click here for subtitle
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Access to NOAC Therapy:
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Valvular heart disease
Oral Anticoagulants in AFa,b A Brief History.
Selecting NOACs for High-Risk Patients
NOACS: Emerging data in ACS/IHD
Access to NOAC Therapy:
Adherence in SPAF: Measures to Improve Care
Which NVAF patients are candidates for NOACs?
Oral Anticoagulation in AF
Relative Risk of Events by CHA2DS2-VASc Score
Dos and Don’ts for High-Risk Elderly Patients With AF
Pradaxa Jeopardy Copyright 2001.
CAD/PAD in Primary Care
A Case Challenge.
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Point-of-Care vs Laboratory INR Testing to Optimize Anticoagulation Management.
Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.
ADAS Anticoagulant Dosing and Advisory Service
NICE 2014 Check pulse in patients presenting with:
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
Presentation transcript:

Which NVAF patients are candidates for TSOACs? Compelling candidates Have NVAF and meet CHADS2 or CHA2DS2VASc criteria for anticoagulation AND ≥1 of the following Poor INR control in spite of good compliance with warfarin Unusual difficulty with regular INR checks True warfarin allergy Understand potential disadvantages (e.g. lack of antidote) and are willing to trade them for convenience of no lab monitoring Less compelling candidates Have indications other than NVAF for anticoagulation (e.g. mechanical heart valve) or an unacceptable risk-benefit ratio for warfarin use Are stable on warfarin with TTR > 72% Have CrCl < 30 ml/min Have poor INR control due to poor compliance Potential financial barriers to care (e.g. no prescription benefit coverage) Other questionable characteristics Age ≥ 75 yoa History of cardiac disease History of GI bleed At this point, I recommend cherry picking vs blanket approach